BDX
Becton, Dickinson and Company NYSE$146.31
Mkt Cap $53.0B
52w Low $127.59
31.3% of range
52w High $187.35
50d MA $160.63
200d MA $154.25
P/E (TTM)
25.6x
EV/EBITDA
10.4x
P/B
1.7x
Debt/Equity
0.8x
ROE
7.0%
P/FCF
12.4x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$160.63
200d MA
$154.25
Avg Volume
2.9M
About
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lin…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | AMC | 2.21 | 2.91 | +31.7% | 162.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% | — |
| Nov 6, 2025 | AMC | 3.92 | 3.96 | +1.0% | 109.63 | -0.2% | +0.3% | +2.4% | +6.6% | +8.3% | +8.8% | — |
| Aug 7, 2025 | AMC | 3.40 | 3.68 | +8.2% | 115.99 | -0.4% | +3.1% | +2.6% | +3.9% | +4.4% | +3.9% | — |
| May 1, 2025 | AMC | 3.28 | 3.35 | +2.1% | 104.79 | +1.0% | -0.4% | -1.5% | -2.6% | -1.4% | -0.9% | — |
| Feb 5, 2025 | AMC | 3.00 | 3.43 | +14.3% | 151.46 | -4.7% | -7.3% | -6.2% | -6.3% | -6.3% | -7.8% | — |
| Nov 7, 2024 | AMC | 3.77 | 3.81 | +1.1% | 140.37 | +0.7% | +2.0% | +3.3% | +1.8% | +1.8% | +0.0% | — |
| Aug 1, 2024 | AMC | 3.31 | 3.50 | +5.7% | 145.86 | +0.4% | +2.5% | -0.1% | -0.2% | -1.4% | -0.7% | — |
| May 2, 2024 | AMC | 2.97 | 3.17 | +6.7% | 148.54 | -0.7% | -2.3% | -1.6% | -1.3% | -2.8% | -2.2% | — |
| Feb 1, 2024 | AMC | 2.40 | 2.68 | +11.7% | 149.79 | +1.0% | -2.1% | -3.0% | -1.5% | -1.2% | -0.7% | — |
| Nov 9, 2023 | AMC | 3.42 | 3.42 | +0.0% | 143.55 | +0.7% | +1.0% | +1.5% | +0.5% | +0.6% | +1.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Evercore ISI | Reiterates | Outperform | $180 | $149.31 | $149.00 | -0.2% | -2.0% | — | — | — | — |
| Apr 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $154.82 | $155.41 | +0.4% | +2.4% | +2.5% | +1.2% | +0.5% | +0.0% |
| Mar 26 | Piper Sandler | Maintains | Neutral → Neutral | — | $158.27 | $156.83 | -0.9% | -0.6% | -2.4% | -2.3% | -0.7% | -1.2% |
| Mar 23 | Argus | Maintains | Buy → Buy | — | $154.13 | $156.68 | +1.7% | +1.4% | +1.2% | +2.7% | +2.1% | +0.2% |
| Feb 11 | Citigroup | Maintains | Buy → Buy | — | $171.68 | $170.67 | -0.6% | +5.2% | +3.6% | +2.5% | +3.3% | +6.4% |
| Feb 10 | JP Morgan | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Jefferies | Maintains | Buy → Buy | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
| Feb 10 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $162.98 | $165.98 | +1.8% | +5.3% | +10.8% | +9.1% | +7.9% | +8.8% |
Recent Filings
8-K · 2.02
!! High
Waters Corporation -- 8-K 2.02: Earnings Results
Waters Corporation reported Q2 2026 financial results, with detailed performance metrics available in the accompanying press release filed as an exhibit.
May 5
8-K · 5.03
! Medium
Becton, Dickinson and Co. -- 8-K 5.03: Amendment to Articles / Bylaws
Becton, Dickinson and Co. amended its bylaws to change its fiscal year, which may affect dividend schedules, earnings reporting timelines, and investor reporting calendars.
Apr 29
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Rick Byrd's retirement after 25 years as a senior executive signals potential leadership transition risks at BD, though investors should monitor whether succession planning adequately addresses any operational or strategic continuity concerns.
Apr 9
8-K
Unknown — 8-K Filing
Becton Dickinson disclosed non-GAAP financial measures in an 8-K filing, suggesting management may be highlighting adjusted metrics that exclude certain charges, which investors should scrutinize to understand actual operational performance.
Apr 2
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals loses director Lynne Kelley, effective March 2, 2026, potentially affecting board oversight and governance as the company navigates its pharmaceutical development pipeline.
Mar 2
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson announced pricing for its tender offers on February 25, 2026, upsizing the offer cap for 4.685% Senior Notes, allowing investors to sell debt back to the company at predetermined rates.
Feb 25
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson commenced tender offers for its debt securities, providing investors with an opportunity to sell holdings back to the company at specified prices.
Feb 10
8-K
Becton, Dickinson and Co. -- 8-K Filing
BD expects to complete its combination of Biosciences and Diagnostic Solutions businesses with Waters Corporation today, following stronger-than-expected Q1 performance.
Feb 9
8-K
Waters Corp -- 8-K Filing
Waters separated from Becton Dickinson, paying BD $4.0 billion and issuing 38.5 million shares to BD shareholders upon merger completion.
Feb 9
8-K · 7.01
! Medium
Becton, Dickinson and Co. -- 8-K 7.01: Regulation FD Disclosure
Becton, Dickinson completed previously announced transactions as of February 9, 2026, signaling execution of strategic initiatives that may impact shareholder value through operational changes or portfolio adjustments.
Feb 9
Data updated apr 24, 2026 9:04pm
· Source: massive.com